Knight Therapeutics (KHTRF)
OTHER OTC:KHTRF
Want to see KHTRF full AI Analyst Report?
KHTRF Stock Chart & Stats
$5.57
-$0.05(-1.39%)
At close: 4:00 PM EST
$5.57
-$0.05(-1.39%)
Day’s Range― - ―
52-Week Range$3.93 - $6.16
Previous CloseN/A
Volume100.00
Average Volume (3M)896.00
Market Cap
$599.28M
Enterprise Value$820.23M
Total Cash (Recent Filing)$95.28M
Total Debt (Recent Filing)$77.91M
Price to Earnings (P/E)16.9
Beta0.03
Next Earnings
Aug 06, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding98,034,744
10 Day Avg. Volume1,740
30 Day Avg. Volume896
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)0.79
Price to Sales (P/S)1.34
P/FCF Ratio8.81
Enterprise Value/Market Cap1.37
Enterprise Value/Revenue1.82
Enterprise Value/Gross Profit4.80
Enterprise Value/Ebitda15.97
Forecast
1Y Price Target
$6.85Price Target Upside23.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.12
Revenue Forecast (FY)$359.37M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA net cash position and ample liquid assets provide durable financial flexibility to fund launches, M&A and buybacks without reliance on new debt. Low leverage reduces refinancing and solvency risk, enabling the company to absorb revenue volatility and invest in long-term commercial expansion.
Robust Launch & BD PipelineA steady cadence of in‑licensing and launches diversifies revenue sources and deepens geographic penetration across Canada and LatAm. Repeatable deal flow and a multi-year launch runway support sustainable top-line growth and reduce dependence on any single product over the medium term.
Improving Cash Generation & MarginsMaterial improvements in revenue, adjusted EBITDA and operating cash flow signal strengthening operating leverage from promoted and newly launched products. Sustained margin expansion and positive FCF enhance the firm's ability to self-fund launches and absorb periodic investment revaluations over the medium term.
Bears Say
Earnings VolatilityRepeated switches between profits and losses indicate weak earnings durability and sensitivity to product mix, one‑off items and revaluations. This instability complicates capital allocation, makes forecasting harder and increases reliance on acquisitions or one-time gains to meet long-term targets.
Regulatory Delay (Qelbree)A 1–2 year delay for a expected new product removes a projected revenue stream and defers peak sales timing, increasing execution risk and forcing greater reliance on other pipeline assets or BD to hit medium‑term growth assumptions, raising strategic execution pressure.
Generic Competition RiskKey products like Ambisome face structural risk from generic entrants; even with slower LatAm erosion (3–5 years), eventual generic competition can materially reduce revenues and margins. The company must continually replace mature product revenue through launches or acquisitions.
Knight Therapeutics News
KHTRF FAQ
What was Knight Therapeutics’s price range in the past 12 months?
Knight Therapeutics lowest stock price was $3.93 and its highest was $6.16 in the past 12 months.
What is Knight Therapeutics’s market cap?
Knight Therapeutics’s market cap is $599.28M.
When is Knight Therapeutics’s upcoming earnings report date?
Knight Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 90 days.
How were Knight Therapeutics’s earnings last quarter?
Knight Therapeutics released its earnings results on May 07, 2026. The company reported $0.095 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.075.
Is Knight Therapeutics overvalued?
According to Wall Street analysts Knight Therapeutics’s price is currently Undervalued.
Does Knight Therapeutics pay dividends?
Knight Therapeutics does not currently pay dividends.
What is Knight Therapeutics’s EPS estimate?
Knight Therapeutics’s EPS estimate is 0.01.
How many shares outstanding does Knight Therapeutics have?
Knight Therapeutics has 98,034,744 shares outstanding.
What happened to Knight Therapeutics’s price movement after its last earnings report?
Knight Therapeutics reported an EPS of $0.095 in its last earnings report, beating expectations of $0.02. Following the earnings report the stock price went up 10.488%.
Which hedge fund is a major shareholder of Knight Therapeutics?
Currently, no hedge funds are holding shares in KHTRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Knight Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.85 (23.06% Upside)
$6.85 (23.06% Upside)
Insider Transactions
Sold Shares
Worth $174.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.85%
12-Months-Change
Fundamentals
Return on Equity
-0.69%
Trailing 12-Months
Asset Growth
13.90%
Trailing 12-Months
Company Description
Knight Therapeutics
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.
KHTRF Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum—record quarterly revenues and adjusted EBITDA, improved gross margin, a stronger balance sheet and an active launch and BD pipeline—supported by raised 2026 guidance. Key challenges include a withdrawal and delayed resubmission of Qelbree's Health Canada filing due to manufacturing changes, a meaningful YoY increase in operating expenses, a small Q1 net loss from investment revaluations, and medium-term risks from potential generic competition and Argentina hyperinflation exposure. Overall, the positive financial results, strengthened liquidity and well-filled launch pipeline materially outweigh the identifiable near-term execution and macro risks.View all KHTRF earnings summariesKHTRF Stock 12 Month Forecast
Average Price Target
$6.85
▲(23.06% Upside)
Technical Analysis
Cipher Pharmaceuticals
―
Organigram Global
―
Aurora Cannabis
―
Cronos Group
―
HLS Therapeutics Inc
―
Ownership Overview
23.49% Insiders
3.69% Mutual Funds
0.09% Other Institutional Investors
71.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---